Diagnostics methods for sleep disorders

The aim of this manuscript is to describe the procedures, recommendations, findings and value of the diagnostic methods used in Sleep Disorders including questionnaires, Actigraph, Polysomnography and Multiple sleep latency test. Specific questionnaires including evaluation of sleep quality , hyper somnolence, Respiratory Sleep Disorders and Sleep-Wake rhythm are in general, used as a screening for the Sleep Disorders and indication of sleep studies. Polysomnogram and Multiple sleep latency test are considered the gold standard methods for the diagnosis of majority of sleep disorders and Narcolepsy respectively. Criteria for these disorders are reported bellow.O objetivo deste artigo é o de descrever os procedimentos, as recomendações, os achados e o valor dos métodos diagnósticos utilizados em transtornos do sono, incluindo questionários, actigrafia, polissonografia e teste múltiplo de latência do sono. Questionários específicos incluindo avaliação da qualidade do sono, hipersonolência, transtornos respiratórios do sono e ritmo sono-vigília são utilizados, em geral, para triar transtornos do sono e como indicação para estudos sobre o sono. A polissonografia e o teste múltiplo de latência do sono são considerados como métodos padrão-ouro na maioria dos transtornos do sono e narcolepsia, respectivamente. Os critérios para tais transtornos são relatados abaixo.Universidade Federal de São Paulo (UNIFESP)UNIFESPSciEL

Sleep hypoventilation

Sleep hypoventilation is seen in patients with neuromuscular disease, as well as in those with obesity hypoventilation syndrome (OHS), which is defined as the combination of obesity, chronic hypercapnia, and hypoxemia during wakefulness that is aggravated during sleep. In 90% of cases, OHS is accompanied by obstructive sleep apnea. The diagnosis of OHS is based on hypoventilation and pulmonary hypertension that cannot be explained by alterations in pulmonary function. The mortality of patients with OHS is greater than is that of obese patients without hypoventilation. The principal neuromuscular diseases associated with OHS are the muscular dystrophies. The progression to chronic respiratory failure results from respiratory muscle weakness and impaired airway secretion clearance, causing atelectasis and pneumonia. With a decrease of greater than 50% in respiratory muscle strength, there is a reduction in VC. Cough peak flow < 160 L/min is associated with impaired airway secretion clearance, and values near 270 L/min indicate the need for assisted cough techniques. Obstructive sleep apnea usually worsens sleep hypoventilation. Noninvasive ventilation during sleep can improve survival, symptoms, and hypoventilation during wakefulness, as well as being able to improve pulmonary function in patients with neuromuscular disease. Patients with OHS can require oxygen therapy.Tanto SHO como as doenças neuromusculares estão relacionadas à hipoventilação durante o sono. Define-se SHO como a combinação de obesidade, hipercapnia e hipoxemia crônica durante a vigília que se agrava durante o sono. Em 90% dos casos, SHO está associada à apneia obstrutiva do sono. O diagnóstico baseia-se na presença de hipoventilação diurna e hipertensão pulmonar que não são justificadas por alterações da função pulmonar. A mortalidade dos pacientes com SHO é maior que aquela de pacientes sem hipoventilação e controlados para obesidade. As doenças neuromusculares são representadas principalmente pelas distrofias musculares. A progressão para insuficiência respiratória crônica surge como consequência da fraqueza dos músculos respiratórios e da limpeza inadequada das vias aéreas, causando atelectasias e pneumonias. Quando há uma redução maior que 50% da forca muscular respiratória, ocorre uma diminuição na CV. A medida do pico de fluxo da tosse < 160 L/min está associada à limpeza inadequada das vias aéreas, e, com valores em torno de 270 L/min, há indicação de uso de técnicas de tosse assistida. A apneia obstrutiva do sono geralmente agrava a hipoventilação durante o sono. O suporte pressórico não invasivo durante a noite pode aumentar a sobrevida, melhorar os sintomas e a hipoventilação diurna. Além disso, no caso de doenças neuromusculares, pode diminuir o declínio da função pulmonar. A oxigenoterapia pode ser necessária nos casos de SHO.Universidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Instituto do SonoEscola Federal de Medicina de Salvador Departamento de Clínica MédicaUNIFESP, EPM, Instituto do SonoSciEL

Treatment of Cheyne-Stokes respiration in patients with congestive heart failure

Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicina (EPM)UNIFESP, EPMSciEL

Sleepiness, inflammation and oxidative stress markers in middle-aged males with obstructive sleep apnea without metabolic syndrome: a cross-sectional study

Background: the simultaneous occurrence of metabolic syndrome and excessive daytime sleepiness are very common in obstructive sleep apnea (OSA) patients. Both conditions, if present in OSA, have been reported to be associated with inflammation and disruption of oxidative stress balance that impair the cardiovascular system. To verify the impact of daytime sleepiness on inflammatory and oxidative stress markers, we evaluated OSA patients without significant metabolic disturbance.Methods: Thirty-five male subjects without diagnostic criteria for metabolic syndrome (Adult Treatment Panel III) were distributed into a control group (n = 10) (43 +/- 10.56 years, apnea-hypopnea index - AHI 2.71 +/- 1.48/hour), a non-sleepy OSA group (n = 11) (42.36 +/- 9.48 years, AHI 29.48 +/- 22.83/hour) and a sleepy OSA group (n = 14) (45.43 +/- 10.06 years, AHI 38.20 +/- 25.54/hour). Excessive daytime sleepiness was considered when Epworth sleepiness scale score was >= 10. Levels of high-sensitivity C-reactive protein, homocysteine and cysteine, and paraoxonase-1 activity and arylesterase activity of paraoxonase-1 were evaluated.Results: Patients with OSA and excessive daytime sleepiness presented increased high-sensitivity C-reactive protein levels even after controlling for confounders. No significant differences were found among the groups in paraoxonase-1 activity nor arylesterase activity of paraoxonase-1. AHI was independently associated and excessive daytime sleepiness tended to have an association with high-sensitivity C-reactive protein.Conclusions: in the absence of metabolic syndrome, increased inflammatory response was associated with AHI and daytime sleepiness, while OSA was not associated with abnormalities in oxidative stress markers.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Associacao Fundo de Incentivo a Pesquisa (AFIP)Universidade Federal de São Paulo UNIFESP EPM, Dept Psychobiol, São Paulo, BrazilUniversidade Federal de São Paulo UNIFESP EPM, Dept Med, São Paulo, BrazilFac Med ABC FUABC, Dept Morphol & Physiol, Santo Andre, SP, BrazilUniversidade Federal de São Paulo UNIFESP EPM, Dept Psychobiol, São Paulo, BrazilUniversidade Federal de São Paulo UNIFESP EPM, Dept Med, São Paulo, BrazilFAPESP: 98/14303-3CNPq: 501343/2010-5Web of Scienc

Obstructive Sleep Apnea A Cardiometabolic Risk in Obesity and the Metabolic Syndrome

Obstructive sleep apnea (OSA) is an underdiagnosed condition characterized by recurrent episodes of obstruction of the upper airway leading to sleep fragmentation and intermittent hypoxia during sleep. Obesity predisposes to OSA, and the prevalence of OSA is increasing worldwide because of the ongoing epidemic of obesity. Recent evidence has shown that surrogate markers of cardiovascular risk, including sympathetic activation, systemic inflammation, and endothelial dysfunction, are significantly increased in obese patients with OSA versus those without OSA, suggesting that OSA is not simply an epiphenomenon of obesity. Moreover, findings from animal models and patients with OSA show that intermittent hypoxia exacerbates the metabolic dysfunction of obesity, augmenting insulin resistance and nonalcoholic fatty liver disease. in patients with the metabolic syndrome, the prevalence of moderate to severe OSA is very high (similar to 60%). in this population, OSA is independently associated with increased glucose and triglyceride levels as well as markers of inflammation, arterial stiffness, and atherosclerosis. A recent randomized, controlled, crossover study showed that effective treatment of OSA with continuous positive airway pressure for 3 months significantly reduced several components of the metabolic syndrome, including blood pressure, triglyceride levels, and visceral fat. Finally, several cohort studies have consistently shown that OSA is associated with increased cardiovascular mortality, independent of obesity. Taken together, these results support the concept that OSA exacerbates the cardiometabolic risk attributed to obesity and the metabolic syndrome. Recognition and treatment of OSA may decrease the cardiovascular risk in obese patients. (C) 2013 by the American College of Cardiology FoundationUniv São Paulo, Sch Med, Heart Inst InCor, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Psicobiol, Disciplina Med & Biol Sono, São Paulo, BrazilJohns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USAUniversidade Federal de São Paulo, Dept Psicobiol, Disciplina Med & Biol Sono, São Paulo, BrazilWeb of Scienc

Interactions between obstructive sleep apnea syndrome and insulin resistance

Previous studies have shown Obstructive Sleep Apnea (OSA) as a risk factor for development of cardiovascular and cerebrovascular disease. However, controversies remain as to whether these changes are consequences of the associated obesity or OSA itself results in endocrine and metabolic changes, including impairment of insulin sensitivity, growth hormone, secretion inflammatory cytokines alterations, activation of peripheral sympathetic activity, and hipothalamic-pituitary-adrenal (HPA) axis, that may predispose to vascular disease. Furthermore many cardiovascular risk factors, such as hypertension, obesity, insulin resistance and type 2 diabetes, are strongly associated with OSA. In this article, we will review the evidence and discuss possible mechanisms underlying these links and the pathophysiology of OSA morbidities.Estudos anteriores mostraram que pacientes com Apnéia Obstrutiva do Sono (AOS) apresentam maior risco para doenças cardiovasculares. Entretanto, permanece controverso se essa associação depende da obesidade ou se ocorre devido a alterações fisiológicas decorrentes da desordem do sono, como ativação do sistema nervoso simpático, da inflamação e desordens do eixo corticotrófico e somatotrófico, que predispõem a danos vasculares. Além disso, muitos fatores de risco para doenças cardiovasculares (DCV) estão fortemente associados ao distúrbio respiratório, entre eles hipertensão, obesidade, resistência à insulina e diabetes tipo 2 (DM2). Neste artigo, vamos discutir a interação entre resistência à insulina e AOS e os possíveis mecanismos fisiopatológicos que contribuem para suas co-morbidades.Universidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Departamento de Clínica MédicaUniversidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Departamento de PsicobiologiaUNIFESP, EPM, Depto. de Clínica MédicaUNIFESP, EPM, Depto. de PsicobiologiaSciEL